A Phase I Study of Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Patients With Logically Advanced Inoperable or Metastatic HER2-Positive Breast Cancer Who Have Received Prior Trastuzumab Based Therapy
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer
- Focus Pharmacokinetics
- Sponsors Roche
- 11 Feb 2018 Planned End Date changed from 10 Sep 2019 to 19 Sep 2019.
- 11 Feb 2018 Planned primary completion date changed from 20 Nov 2018 to 27 Feb 2018.
- 26 Jan 2018 Status changed from recruiting to active, no longer recruiting.